群体检测是否已准备好用于疾病鉴定?
本文探讨群体检测在疾病筛查中的可行性,重点分析设计阶段对混合样本误分类参数假设的合理性。研究发现,若敏感性函数假设错误,会严重低估整体敏感性和预期检测数;而验证研究所需的样本量极大,在多数筛查项目中不可行。
要点
- 设计阶段错误假设混合样本敏感性会低估整体敏感性和检测数
- 验证研究估计混合误分类参数所需样本量极大,多数筛查项目不可行
- 群体检测在医学筛查中的常规应用仍面临方法学挑战
核心结论
- 群体检测在医学筛查中的可行性受限于对混合样本误分类参数的不合理假设。
研究设计与样本
- 本文为方法学论述,探讨群体检测设计中对误分类参数假设的失败影响。
主要发现
- 设计阶段对敏感性函数的错误假设会导致整体敏感性和预期检测数的估计偏差。
- 若用验证研究估计混合误分类参数,所需样本量极大,在多数筛查项目中不可行。
临床怎么用
- 在采用群体检测设计前,应审慎评估混合样本误分类参数假设的合理性。
局限性
- 原文未报告具体数值或系统评价,结论基于方法学讨论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Large-scale disease screening is a complicated process in which high costs must be balanced against pressing public health needs. When the goal is screening for infectious disease, one approach is group testing in which samples are initially tested in pools and individual samples are retested only if the initial pooled test was positive. Intuitively, if the prevalence of infection is small, this could result in a large reduction of the total number of tests required. Despite this, the use of group testing in medical studies has been limited, largely due to skepticism about the impact of pooling on the accuracy of a given assay. While there is a large body of research addressing the issue of testing errors in group testing studies, it is customary to assume that the misclassification parameters are known from an external population and/or that the values do not change with the group size. Both of these assumptions are highly questionable for many medical practitioners considering group testing in their study design. In this article, we explore how the failure of these assumptions might impact the efficacy of a group testing design and, consequently, whether group testing is currently feasible for medical screening. Specifically, we look at how incorrect assumptions about the sensitivity function at the design stage can lead to poor estimation of a procedure's overall sensitivity and expected number of tests. Furthermore, if a validation study is used to estimate the pooled misclassification parameters of a given assay, we show that the sample sizes required are so large as to be prohibitive in all but the largest screening programs.
引用
- Haber G, Malinovsky Y, Albert PS, et al. Is group testing ready for prime-time in disease identification? Stat Med. 2021. PMID: 33913183. doi:10.1002/sim.9003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。